Cellceutix, a clinical stage biopharmaceutical company driving towards the discovery of small molecule drugs for the treatment of unmet medical conditions, announced that its abstract on Kevetrin™, the company's flagship cancer drug candidate currently in clinical trials at Dana-Farber Cencer Center and Beth Israel Deaconess, will be a part of the poster presentation at the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting. The annual ASCO meeting is from May 31 through June 4, 2013, in Chicago, Illinois.
The "General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics" portion of the symposium will feature Cellceutix's abstract titled, "A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors." Clinical and laboratory physicians and staff involved in the study from Dana Farber, Beth Israel Deaconess, and Massachusetts General Hospital, along with Cellceutix scientists, are all listed as authors of the poster presentation.
Upon the notification of their selection, Cellceutix was told that there were over 5,300 submissions for poster consideration given to the Scientific Program Committee and ASCO Leadership.
"We are proud to have been selected to present our research on Kevetrin to the scientific community at ASCO, especially considering the large number of applicants this year," commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "We are particularly pleased to have been selected for presenting during the high-profile General Poster Session, which allots us additional time for our abstract and extra time for a question and answer session. We receive many inquiries about Kevetrin and its progression in clinical trials and this year's ASCO meeting provides a fantastic platform for us to share the research with our peers."
For further information, visit www.cellceutix.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html